Enzon Pharmaceuticals Inc ENZN:OTCQX

RT Quote | Exchange | USD
Last | 3:25 PM EST
0.5157quote price arrow down-0.0243 (-4.50%)
Volume
75,947
52 week range
0.02 - 0.85

...

Loading . . .

KEY STATS

  • Open0.61
  • Day High0.61
  • Day Low0.5157
  • Prev Close0.54
  • 52 Week High0.85
  • 52 Week High Date02/08/21
  • 52 Week Low0.02
  • 52 Week Low Date10/01/20
  • Market Cap38.27M
  • Shares Out74.21M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta0.43
  • 1 Year % Change171.42

RATIOS/PROFITABILITY

  • EPS (TTM)-0.03
  • P/E (TTM)-15.93
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-1.305M
  • ROE (MRQ)-26.40%
  • Revenue (MRQ)50,000.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-2,521.15%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date-
  • Ex Div Date09/30/2019
  • Div Amount0.12
  • Split Date-
  • Split Factor-

Latest Enzon Pharmaceuticals Inc News

There is no recent news for this security.

Latest ENZN News From Our Partners

QUOTE FINDER

Profile

MORE
Enzon Pharmaceuticals, Inc. receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products: PegIntron, Sylatron, Macugen and CIMZIA. The Company has no clinical operations and limited corporate operations. PegIntron is used both as a monotherapy and in combination with REBETOL (ribavirin) capsules for the treatment of chronic hepatitis C. Macugen is used for the treatment of neovascular (wet)...
Randolph Read CPA
Chairman
Richard Feinstein
Chief Executive Officer
Andrew Rackear J.D.
Chief Executive Officer
Address
20 Commerce Drive, Suite 135
Cranford, NJ
07016
United States